Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Abnormal uterine bleeding in adolescents: Management

Nirupama K De Silva, MD
Section Editors
Amy B Middleman, MD, MPH, MS Ed
Mitchell E Geffner, MD
Deputy Editor
Mary M Torchia, MD


Menstrual disorders and abnormal uterine bleeding (AUB) are among the most frequent gynecologic complaints in adolescents. AUB refers to bleeding that is excessive or occurs outside of normal cyclic menstruation [1]. AUB is described by a variety of terms and may be caused by a number of genital and nongenital tract diseases, systemic disorders, and medications (table 1). (See "Abnormal uterine bleeding in adolescents: Evaluation and approach to diagnosis".)

Anovulatory uterine bleeding is the primary cause of AUB in adolescents and generally resolves with maturation of the hypothalamic-pituitary-ovarian axis.

The management of AUB in otherwise healthy adolescents is the focus of this topic review. The management of AUB in adolescents who have chronic disease, have underlying coagulation disorders, or are undergoing chemotherapy or solid organ or hematopoietic stem cell transplantation is beyond the scope of this topic review. Such patients should be managed in conjunction with the appropriate subspecialist. As an example, (see "Heavy or irregular uterine bleeding during chemotherapy").

The evaluation of AUB in adolescents and the evaluation and management of causes of AUB other than anovulatory uterine bleeding in premenopausal women are discussed separately:

(See "Abnormal uterine bleeding in adolescents: Evaluation and approach to diagnosis".)

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Nov 29, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. APGO educational series on women's health issues. Clinical management of abnormal uterine bleeding. Association of Professors of Gynecology and Obstetrics, 2006.
  2. Gray SH, Emans SJ. Abnormal vaginal bleeding in the adolescent. In: Emans, Laufer, Goldstein's Pediatric & Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams & Wilkins, Philadelphia 2012. p.159.
  3. Mitan LA, Slap GB. Adolescent menstrual disorders. Update. Med Clin North Am 2000; 84:851.
  4. Bennett AR, Gray SH. What to do when she's bleeding through: the recognition, evaluation, and management of abnormal uterine bleeding in adolescents. Curr Opin Pediatr 2014; 26:413.
  5. Committee on Practice Bulletins—Gynecology. Practice bulletin no. 136: management of abnormal uterine bleeding associated with ovulatory dysfunction. Obstet Gynecol 2013; 122:176. Reaffirmed 2015.
  6. ACOG Committee Opinion No. 651: Menstruation in Girls and Adolescents: Using the Menstrual Cycle as a Vital Sign. Obstet Gynecol 2015; 126:e143. Reaffirmed 2017.
  7. Rimsza ME. Dysfunctional uterine bleeding. Pediatr Rev 2002; 23:227.
  8. Adams Hillard PJ, Deitch HR. Menstrual disorders in the college age female. Pediatr Clin North Am 2005; 52:179.
  9. Slap GB. Menstrual disorders in adolescence. Best Pract Res Clin Obstet Gynaecol 2003; 17:75.
  10. Gray SH. Menstrual disorders. Pediatr Rev 2013; 34:6.
  11. Bravender T, Emans SJ. Menstrual disorders. Dysfunctional uterine bleeding. Pediatr Clin North Am 1999; 46:545.
  12. Hickey M, Higham JM, Fraser I. Progestogens with or without oestrogen for irregular uterine bleeding associated with anovulation. Cochrane Database Syst Rev 2012; :CD001895.
  13. Strickland JL, Wall JW. Abnormal uterine bleeding in adolescents. Obstet Gynecol Clin North Am 2003; 30:321.
  14. Frishman GN. Evaluation and treatment of menorrhagia in an adolescent population. J Minim Invasive Gynecol 2008; 15:682.
  15. Haamid F, Sass AE, Dietrich JE. Heavy Menstrual Bleeding in Adolescents. J Pediatr Adolesc Gynecol 2017; 30:335.
  16. Srivaths LV, Dietrich JE, Yee DL, et al. Oral Tranexamic Acid versus Combined Oral Contraceptives for Adolescent Heavy Menstrual Bleeding: A Pilot Study. J Pediatr Adolesc Gynecol 2015; 28:254.
  17. American College of Obstetricians and Gynecologists. ACOG committee opinion no. 557: Management of acute abnormal uterine bleeding in nonpregnant reproductive-aged women. Obstet Gynecol 2013; 121:891. Reaffirmed 2017.
  18. James AH, Kouides PA, Abdul-Kadir R, et al. Evaluation and management of acute menorrhagia in women with and without underlying bleeding disorders: consensus from an international expert panel. Eur J Obstet Gynecol Reprod Biol 2011; 158:124.
  19. Bradley LD, Gueye NA. The medical management of abnormal uterine bleeding in reproductive-aged women. Am J Obstet Gynecol 2016; 214:31.
  20. Matteson KA, Rahn DD, Wheeler TL 2nd, et al. Nonsurgical management of heavy menstrual bleeding: a systematic review. Obstet Gynecol 2013; 121:632.
  21. Cowan BD, Morrison JC. Management of abnormal genital bleeding in girls and women. N Engl J Med 1991; 324:1710.
  22. Santos M, Hendry D, Sangi-Haghpeykar H, Dietrich JE. Retrospective review of norethindrone use in adolescents. J Pediatr Adolesc Gynecol 2014; 27:41.
  23. Aksu F, Madazli R, Budak E, et al. High-dose medroxyprogesterone acetate for the treatment of dysfunctional uterine bleeding in 24 adolescents. Aust N Z J Obstet Gynaecol 1997; 37:228.
  24. Munro MG, Mainor N, Basu R, et al. Oral medroxyprogesterone acetate and combination oral contraceptives for acute uterine bleeding: a randomized controlled trial. Obstet Gynecol 2006; 108:924.
  25. Committee opinion no. 606: Options for prevention and management of heavy menstrual bleeding in adolescent patients undergoing cancer treatment. Obstet Gynecol 2014; 124:397.
  26. James AH. Bleeding disorders in adolescents. Obstet Gynecol Clin North Am 2009; 36:153.
  27. Sokkary NA, Venkateswaran L, Dietrich JE, Teruya J. Platelet function disorders and menorrhagia in adolescents: a review of laboratory diagnosis. J Pediatr Adolesc Gynecol 2012; 25:233.
  28. Committee on Adolescent Health Care, Committee on Gynecologic Practice. Committee Opinion No.580: von Willebrand disease in women. Obstet Gynecol 2013; 122:1368.
  29. Zreik TG, Odunsi K, Cass I, et al. A case of fatal pulmonary thromboembolism associated with the use of intravenous estrogen therapy. Fertil Steril 1999; 71:373.
  30. DeVore GR, Owens O, Kase N. Use of intravenous Premarin in the treatment of dysfunctional uterine bleeding--a double-blind randomized control study. Obstet Gynecol 1982; 59:285.
  31. Mannucci PM. Hemostatic drugs. N Engl J Med 1998; 339:245.
  32. Mannucci PM. Treatment of von Willebrand's Disease. N Engl J Med 2004; 351:683.
  33. Hartmann KE, Jerome RN, Lindegren ML, et al. Primary care management of Abnormal Uterine Bleeding. Comparative Effectiveness Review No. 96. Agency for Healthcare Research and Quality, Rockville, MD, 2013. www.ncbi.nlm.nih.gov/books/NBK132510 (Accessed on September 01, 2015).
  34. McCormack PL. Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis. Drugs 2012; 72:585.
  35. Lukes AS, Moore KA, Muse KN, et al. Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol 2010; 116:865.
  36. Ray S, Ray A. Non-surgical interventions for treating heavy menstrual bleeding (menorrhagia) in women with bleeding disorders. Cochrane Database Syst Rev 2016; 11:CD010338.
  37. Strickland J, Gibson EJ, Levine SB. Dysfunctional uterine bleeding in adolescents. J Pediatr Adolesc Gynecol 2006; 19:49.
  38. Conyngham RB. Norethisterone in menorrhagia. N Z Med J 1965; 64:697.
  39. Fraser IS. Treatment of ovulatory and anovulatory dysfunctional uterine bleeding with oral progestogens. Aust N Z J Obstet Gynaecol 1990; 30:353.
  40. Coulam CB, Annegers JF, Kranz JS. Chronic anovulation syndrome and associated neoplasia. Obstet Gynecol 1983; 61:403.
  41. Apter D, Vihko R. Early menarche, a risk factor for breast cancer, indicates early onset of ovulatory cycles. J Clin Endocrinol Metab 1983; 57:82.
  42. World Health Organization multicenter study on menstrual and ovulatory patterns in adolescent girls. II. Longitudinal study of menstrual patterns in the early postmenarcheal period, duration of bleeding episodes and menstrual cycles. World Health Organization Task Force on Adolescent Reproductive Health. J Adolesc Health Care 1986; 7:236.
  43. Widholm O, Kantero RL. A statistical analysis of the menstrual patterns of 8,000 Finnish girls and their mothers. Acta Obstet Gynecol Scand Suppl 1971; 14:Suppl 14:1.
  44. Southam AL, Richart RM. The prognosis for adolescents with menstrual abnormalities. Am J Obstet Gynecol 1966; 94:637.